Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas

Abstract Objective Administration of targeted therapies provides a promising treatment strategy for urachal adenocarcinoma (UrC) or primary bladder adenocarcinoma (PBAC); however, the selection of appropriate drugs remains difficult. Here, we aimed to establish a routine compatible methodological pi...

Full description

Bibliographic Details
Main Authors: Melinda Varadi, Nikolett Nagy, Henning Reis, Boris Hadaschik, Christian Niedworok, Orsolya Modos, Attila Szendroi, Jason Ablat, Peter C. Black, David Keresztes, Anita Csizmarik, Csilla Olah, Nadine T. Gaisa, Andras Kiss, Jozsef Timar, Erika Toth, Erzsebet Csernak, Arpad Gerstner, Vinay Mittal, Sofia Karkampouna, Marianna Kruithof de Julio, Balazs Gyorffy, Gabor Bedics, Michael Rink, Margit Fisch, Peter Nyirady, Tibor Szarvas
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:Cancer Medicine
Subjects:
molecular genetics
Oncomine
primary bladder adenocarcinoma
targeted therapy
urachal cancer
Online Access:https://doi.org/10.1002/cam4.5639

Internet

https://doi.org/10.1002/cam4.5639

Similar Items